Alliance Pharma's sales and profits for H1 2016 more than doubled following the acquisition of Sinclair Health Products last December. Revenue rose 104% to £46.4m, while pre-tax profit was up 113% to £11.7m. UK sales were £24m, compared to £18.3m in 2015, while sales in western Europe were £11.7m, up from 2015's £2.3m and sales outside of western Europe hit £10.7m, compared to £2.2m a year earlier. 63 of Alliance's best-selling brands, scar reduction product Kelo-cote, is sold in One countries and brought in £4.1m in revenue.
Alliance Pharma's sales and profits for H1 2016 more than doubled following the acquisition of Sinclair Health Products last December. Revenue rose 104% to £46.4m, while pre-tax profit was up 113% to £11.7m. UK sales were £24m, compared to £18.3m in 2015, while sales in western Europe were £11.7m, up from 2015's £2.3m and sales outside of western Europe hit £10.7m, compared to £2.2m a year earlier. One of Alliance's best-selling brands, scar reduction product Kelo-cote, is sold in 63 countries and brought in £4.1m in revenue.